VERBUND AG

  • WKN: 877738
  • ISIN: AT0000746409
  • Land: Österreich

Nachricht vom 08.06.2021 | 10:20

VERBUND AG: Chairman of the Supervisory Board resigns

VERBUND AG / Key word(s): Personnel
VERBUND AG: Chairman of the Supervisory Board resigns

08-Jun-2021 / 10:20 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


The Chairman of the Supervisory Board of VERBUND AG, MMag. Thomas Schmid, has informed the company that, following his departure from the Management Board of the Österreichische Beteiligungs AG (ÖBAG), he is resigning his position as a Member and Chairman of the Supervisory Board of VERBUND AG with immediate effect.

Mag. Martin Ohneberg, Deputy Chairman of the Supervisory Board of VERBUND AG, will take over this function on an interim basis until a new Chairman of the Supervisory Board of VERBUND AG has been appointed. A replacement to fill the vacant position on the Supervisory Board will be selected at the General Meeting, the date of which has not yet been decided.

Contact:

Andreas Wollein
Head of Group Finance and Investor Relations
T.: +43 (0)5 03 13 - 52604
F.: +43 (0)5 03 13 - 52694
mailto:investor-relations@verbund.com

08-Jun-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Fresenius Medical Care AG & Co. KGaA passt Besetzung des Vorstands an neues Betriebsmodell an

01. Dezember 2021, 08:30

Aktueller Webcast

HelloFresh SE

Capital Markets Day

08. Dezember 2021

Aktuelle Research-Studie

Li-Metal Corp.

Original-Research: Li-Metal Corp. (von Sphene Capital GmbH): Buy

01. Dezember 2021